Fractyl Health announced it has received two new US patents covering its Revita® duodenal mucosal resurfacing (DMR) technology, expanding its intellectual property portfolio in the field of metabolic disease.
According to the company, the patents protect novel systems and methods used in endoscopic procedures to resurface the duodenal lining, which plays a critical role in metabolic regulation. Fractyl Health claims this innovation supports its ongoing efforts to address the underlying biological causes of type 2 diabetes and obesity rather than only treating symptoms.
The company said that its Revita DMR technology aims to remodel dysfunctional duodenal tissue, which may help restore healthy metabolic signaling. Fractyl Health is currently evaluating the effectiveness of Revita in late-stage clinical trials in both the United States and Europe.
With the addition of these patents, Fractyl Health reports holding over 200 granted and pending patents worldwide. The company stated that this reinforces its leadership in developing device-based metabolic therapies.
Fractyl Health, founded in 2010 and headquartered in Lexington, Massachusetts, focuses on interventions designed to reverse insulin resistance and reduce reliance on lifelong medications. The company claims its expanding intellectual property portfolio will help protect future commercial products and support broader adoption of its technology if regulatory approvals are secured.
The newly granted patents come as Fractyl Health continues to advance its pipeline targeting metabolic diseases, an area of growing global health concern.
